Molecular biomarkers in cancer
VK Sarhadi, G Armengol - Biomolecules, 2022 - mdpi.com
Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis
Simple Summary Growing evidence indicates that blood-count-based compound scores
could be used as prognostic biomarkers in cancer as reflectors of uncontrolled inflammation …
could be used as prognostic biomarkers in cancer as reflectors of uncontrolled inflammation …
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu… - Nature medicine, 2022 - nature.com
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …
endothelial growth factor (VEGF)) combination therapy has become the new standard of …
[PDF][PDF] Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancer
JM Konen, BL Rodriguez, H Wu… - Journal of Clinical …, 2023 - Am Soc Clin Investig
Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are
immunologically warm tumors with partial responsiveness to anti–PD-(L) 1 blockade; …
immunologically warm tumors with partial responsiveness to anti–PD-(L) 1 blockade; …
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in …
J Ning, X Hou, J Hao, W Zhang, Y Shi… - Cell Death & …, 2023 - nature.com
The treatment options for advanced papillary thyroid cancer (PTC) and anaplastic thyroid
cancer (ATC) refractory to standard therapies are limited. Although anti-PD-1 therapy has a …
cancer (ATC) refractory to standard therapies are limited. Although anti-PD-1 therapy has a …
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
WN Liu, WY So, SL Harden, SY Fong, MXY Wong… - Science …, 2022 - science.org
In recent decades, chimeric antigen receptor (CAR)–engineered immune effector cells have
demonstrated promising antileukemic activity. Nevertheless, their efficacy remains …
demonstrated promising antileukemic activity. Nevertheless, their efficacy remains …
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Background: The albumin levels may potentially be used as a prognostic biomarker in
patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close …
patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close …
Lipid nanocarrier-based drug delivery systems: therapeutic advances in the treatment of lung cancer
Although various treatments are currently being developed, lung cancer still has a very high
mortality rate. Moreover, while various strategies for the diagnosis and treatment of lung …
mortality rate. Moreover, while various strategies for the diagnosis and treatment of lung …
The role of immune checkpoint molecules on macrophages in cancer, infection, and autoimmune pathologies
VC Brom, C Burger, DC Wirtz… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors have revolutionized immunotherapy against various cancers
over the last decade. The use of checkpoint inhibitors results in remarkable re-activation of …
over the last decade. The use of checkpoint inhibitors results in remarkable re-activation of …
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
M Muquith, M Espinoza, A Elliott, J Xiu, A Seeber… - Nature Cancer, 2024 - nature.com
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 or its ligand
(PD-1/L1) have expanded the treatment landscape against cancers but are effective in only …
(PD-1/L1) have expanded the treatment landscape against cancers but are effective in only …